Generation Bio Co (GBIO) - Debt to Equity

The market trend for Generation Bio Co. (GBIO) shown on this price chart demonstrates a debt-to-equity ratio of 0.56. The business focuses on creating breakthrough non-viral genetic material delivery methods. Unique patents and strict FDA oversight ensure a high barrier to entry. Current R&D expenses are funded by existing cash reserves.
Comprehensive metric breakdowns and analytics for Generation Bio (GBIO)
- price and consensus price forecast:
- market capitalization data:
- book capitalization data:
- debt and liquidity data:
Basic company analysis:Generation Bio Co. GBIO

Steady demand for Generation Bio Co. (GBIO) biotechnological innovations insulates the business from macroeconomic shocks, creating a foundation for sustainable growth. Analyzing the company's financial leverage dynamics, an investor assesses the debt-to-equity ratio to determine the level of debt burden and the risk of losing control over assets to creditors.
Key competitors
Total Debt to Capital tempus.com (TEM)|Debt to Equity Ratio QGEN|Debt to Equity Ionis Pharma IONS|Debt to Equity Ratio Repligen Inc. (RGEN)|Total Debt to Capital RNA (Avidity Biosciences)|Total Debt to Capital crisprtx.com CRSP|Total Debt to Capital WGS|RARE - Debt to Capital Ratio|Total Debt to Capital BEAM|SRPT (Sarepta Corp) - Debt to Capital|Debt to Equity Twist Bioscience (TWST)|Debt to Equity Ratio 10xgenomics.com|Intellia Therapeutics, Inc. - Total Debt to Capital|Debt to Capital STOK (Stoke Therapeutics Inc)|Debt to Equity BioLife Corp|All Debt to Shareholders' Equity Ratio Wave Pharma WVE|Maze Therapeutics Inc - Total Debt to Capital|sionnatx.com (SION) - Total Debt to Capital|PRME - Total Debt to Equity Ratio|Taysha Gene Therapies Inc (TSHA) - Aggregate Debt to Capital|QURE: Total Debt to Capital|Total Debt to Capital Coefficient MGTX|REGENXBIO Inc. - Debt to Equity|Debt to Capital SLDB (solidbio.com)|OCGN - Debt to Equity|PACB - Debt to Equity Ratio|Total Debt to Equity Ratio Benitec (BNTC)|DSGN - All Debt to Shareholders' Equity Ratio|Rocket Pharmaceuticals (RCKT) - Total Debt to Capital|4dmoleculartherapeutics.com (FDMT) - Debt to Equity|LXEO: Total Debt to Capital|Total Debt to Capital Coefficient KRRO|Editas - Debt to Equity|Debt to Capital Silence Therapeutics Corp SLN|Total Debt to Equity Ratio ProQR Therapeutics|All Debt to Shareholders' Equity Ratio Codexis Inc CDXS|SGMO: Total Debt to Capital|NAUT: Total Debt to Equity Ratio|Debt to Equity MGX|Debt to Capital Precision BioSciences Inc.|BOLD: Total Debt to Equity Ratio|Total Debt to Capital Coefficient Exicure Corp|IMNN: Total Debt to Capital|Debt to Capital Ratio phiopharma.com (PHIO)|Total Debt to Capital Mustang Bio MBIO|Debt to Equity TransCode Therapeutics Inc. RNAZ|Total Debt to Capital BNGO (Bionano)|APDN: Total Debt to Capital Coefficient|Debt to Equity BLUE|ImmunoPrecise Antibodies Ltd. (IPA) - Debt to Capital|Total Debt to Capital Omega (OMGA)|Debt to Equity Ratio OMIC|Debt to Equity Regulus Therapeutics RGLS|Debt to Equity Ratio syros.com (SYRS)|Total Debt to Capital TBIO (Telesis Bio)|Total Debt to Capital TRACON Pharmaceuticals Inc. TCON|Total Debt to Capital UBX